Truist Financial
ALZN icon

Truist Financial’s Alzamend Neuro ALZN Stock Holding History

Truist Financial’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,722
Closed -$14.7K – 2594
2025
Q1 		$14.7K Hold
1,722
– – ﹤0.01% 2530
2024
Q4 		$18K Hold
1,722
– – ﹤0.01% 2498
2024
Q3 		$26.2K Hold
1,722
– – ﹤0.01% 2469
2024
Q2 		$61.1K Buy
1,722
+7
+0.4% +$400 ﹤0.01% 2606
2024
Q1 		$154K Hold
1,715
– – ﹤0.01% 2524
2023
Q4 		$137K Hold
1,715
– – ﹤0.01% 2542
2023
Q3 		$549K Hold
1,715
– – ﹤0.01% 1873
2023
Q2 		$1.18M Hold
1,715
– – ﹤0.01% 1509
2023
Q1 		$984K Hold
1,715
– – ﹤0.01% 1560
2022
Q4 		$1.31M Hold
1,715
– – ﹤0.01% 1422
2022
Q3 		$2.75M Hold
1,715
– – 0.01% 1021
2022
Q2 		$2M Hold
1,715
– – ﹤0.01% 1215
2022
Q1 		$2.85M Buy
+1,715
New +$3.22M ﹤0.01% 1130

Other funds holding ALZN

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Truist Financial's ALZN Position: Q2 2025 in Review

Truist Financial sold out of Alzamend Neuro (ALZN) in Q2 2025, closing a stake of 1,722 shares — an estimated $14.7K sold.

Truist Financial first reported a position in ALZN in Q1 2022 and held it in 13 quarters. The position peaked at $2.85M in Q1 2022. 7 funds tracked by Wall St. Rank hold ALZN as of Q2 2025.

  • Truist Financial reported no remaining Alzamend Neuro position as of Q2 2025 after selling out during the quarter.
  • Truist Financial sold 1,722 Alzamend Neuro shares in Q2 2025, an estimated $14.7K.
  • Truist Financial first reported a position in Alzamend Neuro in Q1 2022 and held it in 13 quarters.
  • Truist Financial's Alzamend Neuro position peaked at $2.85M in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2025.

Based on Truist Financial's 13F filing for Q2 2025, filed 18 Jul 2025.